Immunology Market Size, Share and Industry Analysis By Drug Class (Monoclonal antibody (mAb), Fusion Proteins, Immunosuppressant, Polyclonal antibody (pAb), Others), By Disease Indication (Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, Prophylaxis of Organ Rejection, Others), By Distribution Channel, and Regional Forecast 2020-2029 (Includes COVID-19 Business Impact)

                                          
We have updated Immunology Market with respect to COVID-19 Business Impact.
Inquire before buying


This report focuses on the Immunology market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Immunology market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.


Global Immunology Market: Segment Analysis


The research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.


Global Immunology Market: Regional Analysis


The research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.


Global Immunology Market: Competitive Landscape


This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029.
List of Companies Profiled

  
AbbVie Inc.
  
Janssen Global Services, LLC (Johnson & Johnson)
  
F. Hoffmann-La Roche Ltd
  
Amgen Inc.
  
Pfizer Inc.
  
Novartis AG
  
Astellas
  
Bristol-Myers Squibb Company
  
Merck Sharp & Dohme Corp.
  
UCB SA
  
ALLERGAN
  
Other Prominent Players

Report Coverage

The increasing prevalence of a number of autoimmune and immunological disorders in the general population is one of the key factors boosting the global immunology market revenue. The increasing R&D initiatives in the immunology industry and the recent regulatory approvals are also positively contributing to the growth of the market. The introduction of new products in the market, along with an increasing number of patients undergoing treatment for immunological diseases globally is projected to further augment the demand for immunology drugs during the forecast period.

The report provides qualitative and quantitative insights on the immunology industry trends and detailed analysis of immunology market size and growth rate for all possible segments in the market. The market segments include drug class, disease indication, distribution channel, and geography.

On the basis of the drug class, the global market segments include monoclonal antibody (mAb), fusion proteins, immunosuppressants, polyclonal antibody (pAb) and others. On the basis of disease indication, the market is categorized into rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, inflammatory bowel disease, prophylaxis of organ rejection and others. On the basis of the distribution channel, the immunology industry is categorized into hospital pharmacies, retail pharmacies, online pharmacies, and others.
Along with this, the report analysis includes market dynamics and competitive landscape. Various key insights provided in the report are the prevalence of autoimmune and immunological disorders by key countries, regulatory scenario by key regions, key industry developments, overview of regulatory scenario by key countries, an overview of current advances in R&D for immunology.

SEGMENTATION 

By Drug Class

  
Monoclonal antibody (mAb)
  
Fusion Proteins
  
Immunosuppressants
  
Polyclonal antibody (pAb)
  
Others

By Disease Indication

  
Rheumatoid Arthritis
  
Psoriatic Arthritis
  
Plaque Psoriasis
  
Ankylosing Spondylitis
  
Inflammatory Bowel Disease
  
Prophylaxis of Organ Rejection
  
Others

By Distribution Channel

  
Hospital Pharmacies
  
Retail Pharmacies
  
Online Pharmacies
  
Others

By Geography

  
North America (U.S., and Canada)
  
Europe (Germany, U.K., France, Italy, Spain, Scandinavia, and Rest of Europe)
  
Asia Pacific (China, India, Japan, Australia, South East Asia, and Rest of Asia Pacific)
  
Latin America (Brazil, Mexico, and the Rest of Latin America)
  
Middle East & Africa (GCC, South Africa, and Rest of Middle East & Africa)

Key Industry Developments

In April 2019, Novartis AGs product offering of Cosentyx (secukinumab) for the treatment of moderate to severe psoriasis was approved in China

In April 2019, AbbVie Inc. extended their immunology portfolio with the launch of their new product offering of SKYRIZI (risankizumab-rzaa) for the treatment of moderate to severe plaque psoriasis

In July 2017, Janssen Global Services, LLC (Johnson & Johnson) announced the launch of TREMFYA (guselkumab) for the treatment of moderate to severe plaque psoriasis